Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 5/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22549439 | 0.88 | NSD2 (0.42) | PRMT5WDR77SYK | |
| SCHEMBL29501351 | 0.88 | NSD2 (0.42) | PRMT5WDR77SYK | |
| SCHEMBL23684309 | 0.83 | PRMT5 (0.36) | FLT3PRMT5WDR77EGLN2NQO2 | |
| SCHEMBL23683982 | 0.83 | PRMT5 (0.40) | FLT3PRMT5WDR77 | |
| SCHEMBL2791038 | 0.82 | S1PR1 (0.42) | SYK | |
| SCHEMBL20502047 | 0.82 | S1PR1 (0.39) | SYKNQO2 | |
| SCHEMBL23304437 | 0.81 | GBA1 (0.44) | PRMT5WDR77EGLN2 | |
| SCHEMBL23683938 | 0.81 | ALDH1A1 (0.43) | — | |
| SCHEMBL23304429 | 0.81 | SYK (0.39) | PRMT5WDR77SYKNQO2PCSK9 | |
| SCHEMBL2786922 | 0.81 | S1PR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022237858-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | FLT3 2553/4885PRMT5 1715/4885WDR77 4713/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | FLT3 2391/4885PRMT5 459/4885WDR77 4537/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | FLT3 2553/4885PRMT5 1715/4885WDR77 4713/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | FLT3 2391/4885PRMT5 459/4885WDR77 4537/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | FLT3 2553/4885PRMT5 1715/4885WDR77 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.